0000950170-23-033652.txt : 20230720 0000950170-23-033652.hdr.sgml : 20230720 20230720145548 ACCESSION NUMBER: 0000950170-23-033652 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230720 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100] IRS NUMBER: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37383 FILM NUMBER: 231099421 BUSINESS ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 105 CITY: DAVIS STATE: X1 ZIP: 95618 BUSINESS PHONE: 530-756-7077 MAIL ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 105 CITY: DAVIS STATE: CA ZIP: 95618 8-K 1 rkda-20230720.htm 8-K 8-K
false000146944300014694432023-07-202023-07-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2023

 

 

Arcadia Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37383

81-0571538

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

5950 Sherry Lane

Suite 215

 

Dallas, Texas

 

75225

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 214 974-8921

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common

 

RKDA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On July 20, 2023, Arcadia Biosciences, Inc. (the “Company”) issued a press release (“Press Release”) announcing the Company’s cash and cash equivalents position as of June 30, 2023 and the Company’s expected range of revenue for the second quarter of 2023.

 

The Press Release also announced the Company’s strategic review to explore a range of strategic and financing alternatives focused on maximizing long-term stockholder value.

 

A copy of the Press Release is filed with this Report as Exhibit 99.1, and is incorporated herein by reference.

Item 8.01 Other Events.

The disclosures in Item 2.02 of this Form 8-K are incorporated by reference into this Item 8.01.

 

Forward-Looking Statements

 

This Current Report on Form 8-K, and the press release filed as an exhibit to this Report, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s reduction in expenses from the streamlining of its operations and exiting ProVault and SoulSpring, the Company’s review and evaluation of potential strategic alternatives and their impact on stockholder value, the process by which the Company engages in evaluation of strategic transactions, the Company’s ability to identify potential buyers or partners for the Company’s commercial products, the Company’s ability to identify potential sellers or merger or acquisition partners, and the terms, timing, structure, benefits and costs of any strategic transaction. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to: the Company’s ability to reduce costs from streamlining its operations and exiting ProVault and SoulSpring; the results of its strategic review process; the Company’s cash flow, cash burn, expenses, obligations and liabilities; the interest of third parties in entering into a merger, reverse merger, asset sale, partnership arrangement or other strategic transaction with the Company or in purchasing one or more of its commercial products; any impact of this evaluation process on the sale of the Company’s commercial products; and other important factors and risks discussed in the Company’s filings with the Securities and Exchange Commission, including those risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated July 20, 2023

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARCADIA BIOSCIENCES, INC.

 

 

 

 

Date:

July 20, 2023

By:

/s/ THOMAS J. SCHAEFER

 

 

 

Thomas J. Schaefer, Chief Financial Officer

 

 EX-99.1 2 rkda-ex99_1.htm EX-99.1 EX-99.1

img192114479_0.jpg

 

Arcadia Biosciences (RKDA) Announces Strategic Review

 

– Company will explore a range of potential strategies to drive shareholder value –

 

DAVIS, Calif. (July 20, 2023) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today disclosed that it has initiated a process to explore a range of potential transactions and alternative strategies focused on maximizing long-term shareholder value.

 

As part of this process, the company will explore strategic options that may include the potential for an acquisition, company sale, merger, business combination, asset sale, joint venture, licensing arrangement, capital raise or other strategic transaction.

 

Lake Street Capital Markets, LLC, will act as Arcadia’s financial advisor with respect to the strategic review process. There can be no assurance that this exploration of strategic alternatives will result in the company entering or completing any transaction, and no timetable has been set for the conclusion of the strategic review.

 

“This review is in line with Project Greenfield, our 3-year plan to maximize the company’s potential and drive shareholder value,” said Stan Jacot, Arcadia’s CEO. “We see this as an opportune time to undertake these efforts after closing the second quarter of 2023 in an excellent cash position and streamlining our operating expenses in anticipation of challenging economic headwinds.”

 

Business Update

As of June 30, 2023, Arcadia Biosciences had approximately $18.8 million in cash and cash equivalents. The company anticipates second-quarter revenue in the range of $1.3 million - $1.5 million. As part of the Project Greenfield strategy to focus resources on high-opportunity, scalable businesses, Arcadia has made the decision to streamline its operations and exit the remaining body care brands, ProVault and SoulSpring, which the company expects to result in annual operating expense savings of $3 million to $4 million starting in August 2023. Arcadia also recently announced an expanded GoodWheat portfolio with the launch of GoodWheat pancake mixes. Arcadia Biosciences expects to announce its second-quarter financial results on August 10, 2023.

 

About Arcadia Biosciences, Inc.

Since 2002, Arcadia Biosciences has been innovating crops to provide high-value, healthy ingredients to meet consumer demand for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products that make everybody feel good, inside and out. The

company’s food and beverage products include GoodWheat™ and Zola® coconut water. For more information, visit arcadiabio.com.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s reduction in expenses from the streamlining of its operations and exiting ProVault and SoulSpring, the company’s review and evaluation of potential strategic alternatives and their impact on stockholder value; the process by which the company engages in evaluation of strategic transactions, the company’s ability to identify potential buyers or partners for the company’s commercial products, the company’s ability to identify potential sellers or merger or acquisition partners, and the terms, timing, structure, benefits and costs of any strategic transaction. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to: Arcadia’s ability to reduce costs from streamlining its operations and exiting body care; the results of its strategic review process; the company’s cash flow, cash burn, expenses, obligations and liabilities; the interest of third parties in entering into a merger, reverse merger, asset sale, partnership arrangement or other strategic transaction with the company or in purchasing one or more of its commercial products; any impact of this evaluation process on the sale of the company’s commercial products; and other important factors and risks discussed in the company’s filings with the Securities and Exchange Commission, including those risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2022. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

Investor Contact:

T.J. Schaefer

Chief Financial Officer

ir@arcadiabio.com

# # #

 

 GRAPHIC 3 img192114479_0.jpg GRAPHIC begin 644 img192114479_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BH;JZALK:2YN)!'#&-S,>PKDGNM?\3DFP/]F:8?NS/Q)(/4=_RQ M]:QJUE#1*[?1$3J*.F[.PDFBB_UDJ)_O,!2I(D@RCJP]5.:XU?AW:R#=IFZE5:\GXG>T5P MVD^+;W3[T:;XAC*,#@3L,$>F['!'N*[D$$ @Y![UM1KPK*\>G3JBZ=2,UH%% M%%;&@4444 %%%% !1110 4444 %%%% &!>VW]NZV+27G3[':\J=I92,JI]@. M?Q%5O&RQG3+6/ #^=\N.P"G/]*V],B$<$S_Q2SR.W_?1 _0"N6\3W)NM96W7 ME8%"X_VCR?Z5Y^*M&A)O>7]?@CGJ64&^K*>F:-JSVBWEC.R@D@!92IX]NE;% MGXAO;&86^L0L!_SUVX8>Y'0CW%=!96IM-.BMD.UD3&??N?SJ"(6^MZ8//C!Y M*.O='!P<'ZBG3PI7U[1;;Q!IF!M\X+N@F'8_7T-9O@; M4Y;BQFTVY)\^R;: W79TQ^!!'Y5>T/SM/O+C2)F++&/-@8]T)Y_7^M95@GV3 MXEWT%O% MOF2(Q@,AD0C^*-NH'N,_I7G8[W7"3^%/4YJ[MRM[7/3*YCPQ>;]:\16.>(+S MS%'IO'/ZBNAM;N"]MUGMI5EB89#*:\Z\":@MU\0?%C!AY>\G.>.'85ZU)*5. M4EV_4W;U1W\]L6U.TN5'*!T8^Q'^(KGM!/\ :7C'5]47F"("WC;L2,9Q_P!\ M_K3]7U^34I6T?0#Y]S)\LMPOW(5[G/K_ )ZUMZ/I<.C:9%90\A!EF/5V/4UY MVE6JN79.[?G:UO\ ,RTG/39?F7Z***[#<**** "BBB@ HHHH **^9/%'Q#\9 M:OJ_B36O#FKS6^A:3-%$%CQMVLVQ6Z<[B"?QKZ!\)>((?%/A73M:AP!=0AG4 M?P..'7\&!% &U1110 54U#3;/5+8P7D"RIU&>"I]0>QJW12<5)68FDU9G%77 MA!-&AGU"PU"^18$,OD1CZUVTO;1)I(RJ2* M8C*?F9NHR1EA7L]%%*%.E2G2C'25K_(R]A!/38K6.GVFFVX@L[=(8_11U^I[ MU9HHH225D:I):(**\Y^-VI7VD_#F:ZTZ\N+2X%S$HE@D*-@DY&1S7*S^(/'J M?!CPO?>&A=WM].7^V7"Q?:9\;FV\$'(/0G'&!3&>X45E^&YM4N?#6FS:U"L. MIO;HUS&HP%?'/';Z=JU* "BBB@!"P52S$ #DD]J\T^*/Q)TG1O"&I6NFZG!- MJUPGV>)(6W%-W#-D< @9/UQ7I;*KJ590RGJ",@U\^>/G/Q$^-.E>#[8YTW36 MVW 3H#]Z4_@H"?7ZT 7OA7'X-E^&-SXC*=LBC_QUA^)KU;7? WAGQ):F#4]&M9? MEVK(L821/3##!%?/7BOPKJ'P<\>:3K]I<2WFG&?=#*Y^? X>)_X^E ' M6?&GQ'J?ASXD^'+NPGN2D<"2FT29E29A*V R@\YZ5MV7@/5[&XB\<>-/%MV] MU8_Z=-:0C]S$JC<8QSCVP /QZUR?QENX-0^(W@R\MI!);W$$$L;CHRM-D'\C M7L_Q TNYUKP!KFGV:EKF:U;RT'5V'.T?7&/QH \ET6\\9?&K5+RX35Y] \,V M\GEA+4D.YZ[<@@LV,$DG R,"NG_X499P 26/BWQ';70.?-^T@_H #^M9/[// MB33_ /A'KKPY+*D.I17+3)$YP948 9'J00S>)M6$USXJUF MUTU8E06-K-L!8=6+"-&FUSPGXUOX;^S*L]K-?JYE7(! MP!CD9S@@@@&H+6[O_BY\5=4T/5M5N;'1=/\ -*6%O)L,H1PF#ZDYR2\$82VEDGD9VD)&, MR>O;IF@"Q)\8I;7X-6GB26 M&)]:N)<CQ\AF7.7(]-HW8]2!6=X7^&FM^.-+@\0^,O%&K![U1-!:VTNS8A MY4G((&1S@ 8XKS?4-,N;GX#Z-J,2,T%GJMPLV/X0X4!C[97'_ A7TKX!U^P\ M1>"M+O+&5&"V\<4L:GF*15 92.W(_$8- 'BWQ7\(Z]X.\(F"WUZ[U3P[<3HK MPWQWRVT@R5*M_=.".,?3O5;Q/J5_IGP"\%26%[<$@UW'[ M0NLV-OX'CTEYT-]=7*.D(/S;%R2Q'8=!^->>^-/^3??!'_7P_P#[4H ]I.@Z MAXK^'GAVW@\0W^ER&TMY+B>V;]Y,IB&5+9R"20<_SKF-4^$'A^T@8KXTUBRU M'&4N+G4%^]ZD8!Q]"*Y;QMXNUF.T\$>#=-U!]+M[[3+)KB[0[6(D 0#=U"C! M)P1G->@V?P6\":;:-+?V3WLB+NFNKVY?)P.6."%'Y4 87P1\<:OK%SJGAK6[ MO[;<:>-\-T6W,RAMK M_$,X(/7D^U>R5\Y_ ?[)_PM'Q)]@V_8_L\OV?;G'E M^>F*^C* \@X.#ZUQ7A#X9Z3X/UR_UFWN[V\O[T$22W;*2,MN;&U1U. M,_2NUHH *Y_QEX/T[QOH)TG4VE2+S%E22$@.C#N,@CH2.G>H_%TVNPPV7]AB M3.+"LRS;,@?W2=W'I M5\FB=]Q7.+F^"NB7 T3SM4U20Z.@2W+/'DJ)"X#?)S@G'&.,5Z565J,FK+X7 MFDTZ-'U;[-F))< &3'?MU_"JNCS:K)J\ZRBX;2Q;1E)+N-4E\_)W 97&WM MUZ$]A0T;N%]3G/%/P;\+^)]0?4@MQINH.V]Y[)PN]O[Q4@C/N,$UEI\$()=L M>H^,?$5W;@_ZDW.!^N:[AYM9C\7)&J--I4BX.%V>00I.22"'!.!P00>Q'-/U MF74TU2P2'SUTQED^TR6R!Y _&P8()"_>R0"<@=!1R:I7"YRGB3X.:)KFM_VW M9W]_I.J$[GN+.0#>V,%B.S'N01FDA^#6BS17#:WJ>JZW=2PO"D]_<;_(W#&Z M-3P&'4$YYKM-3DOD\,7DE@)6U 6;M!N1=YEV';D=,YQQTJ/4Y-43PC=2V:L= M5%DS1*%!/G;..#Q][MTI*-^H7,[POX#TGPQX6G\.H9;[3YW=Y$O-K;@P *G M QQ7'S? ?1X-0>ZT+7=8T<2?>CMIN /0'AL?4FO3-*>9].B-P9#-CYS(NTY[ M\8'%8NAMXECU&*'52L]F\+RKI]3^$FBZKX,TKPO/?:@MIID MC/%(C)YC$[OO';C^(] *Z'4Y=477D0?:DTO[*2LEI&KN9]W1L@X&W&.,$YR> ME3^))=4B\-74FD*[:@%3R@JAF^\,\'CIFA0U2ON%S!\1_"[P]XHT#3M+OA.' MTZ!8+:[C8"5550,'C!!P#C'TQ6/:?!BT*QP:QXHU_5;"/&VRFNBL1 Z @=OI MBO0XVE.EDJTGG>6V&>/+;N>=IQGGMQFJ'AF;59=/E75XB+B.78)>@F7 ^<*0 M"HR3P>F#R1BERZ-ATN6YC>\C:,VORB&-2P;"@*",%1CF KNTHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$! end EX-101.LAB 4 rkda-20230720_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 5 rkda-20230720_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 rkda-20230720.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Jul. 20, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 20, 2023
Entity Registrant Name Arcadia Biosciences, Inc.
Entity Central Index Key 0001469443
Entity Emerging Growth Company false
Securities Act File Number 001-37383
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-0571538
Entity Address, Address Line One 5950 Sherry Lane
Entity Address, Address Line Two Suite 215
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75225
City Area Code 214
Local Phone Number 974-8921
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol RKDA
Security Exchange Name NASDAQ
XML 8 rkda-20230720_htm.xml IDEA: XBRL DOCUMENT 0001469443 2023-07-20 2023-07-20 false 0001469443 8-K 2023-07-20 Arcadia Biosciences, Inc. DE 001-37383 81-0571538 5950 Sherry Lane Suite 215 Dallas TX 75225 214 974-8921 false false false false Common RKDA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports rkda-20230720.htm rkda-20230720.xsd rkda-20230720_lab.xml rkda-20230720_pre.xml rkda-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rkda-20230720.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "rkda-20230720.htm" ] }, "labelLink": { "local": [ "rkda-20230720_lab.xml" ] }, "presentationLink": { "local": [ "rkda-20230720_pre.xml" ] }, "schema": { "local": [ "rkda-20230720.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rkda", "nsuri": "http://arcadiabio.com/20230720", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rkda-20230720.htm", "contextRef": "C_c43ff991-973d-4efe-a6c2-245b41d7ec43", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rkda-20230720.htm", "contextRef": "C_c43ff991-973d-4efe-a6c2-245b41d7ec43", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://arcadiabio.com/20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-033652-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-033652-xbrl.zip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end